Barclays analyst Luke Sergott lowered the firm’s price target on Exact Sciences (EXAS) to $55 from $65 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Mizuho ‘bullish’ on Exact Sciences, starts at Outperform
- Exact Sciences initiated with an Outperform at Mizuho
- Strategic Developments and Product Launch Drive Buy Rating for Exact Sciences
- Exact Sciences announces launch of Cologuard Plus test
- Exact Sciences Positioned for Growth with Upcoming Product Launches and Margin Expansion
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue